Suppr超能文献

肠道菌群失调与肠道疾病:机制与治疗。

Gut dysbacteriosis and intestinal disease: mechanism and treatment.

机构信息

Key Laboratory for Molecular Enzymology and Engineering of Ministry of Education, College of Life Science, Jilin University, Changchun, PR China.

InnovHope Inc, Framingham, MA, USA.

出版信息

J Appl Microbiol. 2020 Oct;129(4):787-805. doi: 10.1111/jam.14661. Epub 2020 May 19.

Abstract

The gut microbiome functions like an endocrine organ, generating bioactive metabolites, enzymes or small molecules that can impact host physiology. Gut dysbacteriosis is associated with many intestinal diseases including (but not limited to) inflammatory bowel disease, primary sclerosing cholangitis-IBD, irritable bowel syndrome, chronic constipation, osmotic diarrhoea and colorectal cancer. The potential pathogenic mechanism of gut dysbacteriosis associated with intestinal diseases includes the alteration of composition of gut microbiota as well as the gut microbiota-derived signalling molecules. The many correlations between the latter and the susceptibility for intestinal diseases has placed a spotlight on the gut microbiome as a potential novel target for therapeutics. Currently, faecal microbial transplantation, dietary interventions, use of probiotics, prebiotics and drugs are the major therapeutic tools utilized to impact dysbacteriosis and associated intestinal diseases. In this review, we systematically summarized the role of intestinal microbiome in the occurrence and development of intestinal diseases. The potential mechanism of the complex interplay between gut dysbacteriosis and intestinal diseases, and the treatment methods are also highlighted.

摘要

肠道微生物群的功能类似于内分泌器官,产生生物活性代谢物、酶或小分子,这些物质可以影响宿主的生理机能。肠道菌群失调与许多肠道疾病有关,包括(但不限于)炎症性肠病、原发性硬化性胆管炎-肠病、肠易激综合征、慢性便秘、渗透性腹泻和结直肠癌。与肠道疾病相关的肠道菌群失调的潜在致病机制包括肠道微生物群组成的改变以及肠道微生物群衍生的信号分子。后者与肠道疾病易感性之间的许多相关性使肠道微生物群成为治疗的潜在新靶点。目前,粪便微生物移植、饮食干预、益生菌、益生元和药物是用于影响菌群失调和相关肠道疾病的主要治疗工具。在这篇综述中,我们系统地总结了肠道微生物群在肠道疾病发生和发展中的作用。还强调了肠道菌群失调与肠道疾病之间复杂相互作用的潜在机制和治疗方法。

相似文献

1
Gut dysbacteriosis and intestinal disease: mechanism and treatment.
J Appl Microbiol. 2020 Oct;129(4):787-805. doi: 10.1111/jam.14661. Epub 2020 May 19.
2
Restoration of dysbiotic human gut microbiome for homeostasis.
Life Sci. 2021 Aug 1;278:119622. doi: 10.1016/j.lfs.2021.119622. Epub 2021 May 17.
3
Therapeutic Potential of the Gut Microbiota in the Prevention and Treatment of Sepsis.
Front Immunol. 2018 Sep 10;9:2042. doi: 10.3389/fimmu.2018.02042. eCollection 2018.
5
Current understanding of microbiota- and dietary-therapies for treating inflammatory bowel disease.
J Microbiol. 2018 Mar;56(3):189-198. doi: 10.1007/s12275-018-8049-8. Epub 2018 Feb 28.
6
Role of Probiotics in Human Gut Microbiome-Associated Diseases.
J Microbiol Biotechnol. 2019 Sep 28;29(9):1335-1340. doi: 10.4014/jmb.1906.06064.
7
Gut microbiota and inflammatory bowel disease: so far so gut!
Minerva Gastroenterol Dietol. 2017 Dec;63(4):373-384. doi: 10.23736/S1121-421X.17.02386-8. Epub 2017 Mar 14.
8
Implications of Gut Microbiota in Complex Human Diseases.
Int J Mol Sci. 2021 Nov 23;22(23):12661. doi: 10.3390/ijms222312661.
9
Microbiota modulation-based therapy for luminal GI disorders: current applications of probiotics and fecal microbiota transplantation.
Expert Opin Biol Ther. 2019 Dec;19(12):1343-1355. doi: 10.1080/14712598.2019.1673725. Epub 2019 Oct 13.
10
Inflammatory Bowel Diseases (IBD) and the Microbiome-Searching the Crime Scene for Clues.
Gastroenterology. 2021 Jan;160(2):524-537. doi: 10.1053/j.gastro.2020.09.056. Epub 2020 Nov 27.

引用本文的文献

2
Effects of tea polysaccharides on gut microbiota and physiological health indicators in mice.
Sci Rep. 2025 Jul 10;15(1):24879. doi: 10.1038/s41598-025-09402-3.
3
Liposomal and Lipid-Based Drug Delivery Systems: Bridging Gut Microbiota and Pediatric Disorder Treatments.
Pharmaceutics. 2025 May 28;17(6):707. doi: 10.3390/pharmaceutics17060707.
4
The power of microbes: the key role of gut microbiota in the initiation and progression of colorectal cancer.
Front Oncol. 2025 Apr 14;15:1563886. doi: 10.3389/fonc.2025.1563886. eCollection 2025.
8
Gut Microbiome as a Target for Anti-ageing Interventions.
Subcell Biochem. 2024;107:307-325. doi: 10.1007/978-3-031-66768-8_14.
9
Gut microbiota changes associated with frailty in older adults: A systematic review of observational studies.
World J Clin Cases. 2024 Dec 16;12(35):6815-6825. doi: 10.12998/wjcc.v12.i35.6815.

本文引用的文献

1
Impact of a high‑fat diet on intestinal stem cells and epithelial barrier function in middle‑aged female mice.
Mol Med Rep. 2020 Mar;21(3):1133-1144. doi: 10.3892/mmr.2020.10932. Epub 2020 Jan 13.
3
Microbial bile acid metabolites modulate gut RORγ regulatory T cell homeostasis.
Nature. 2020 Jan;577(7790):410-415. doi: 10.1038/s41586-019-1865-0. Epub 2019 Dec 25.
4
Bile acid metabolites control T17 and T cell differentiation.
Nature. 2019 Dec;576(7785):143-148. doi: 10.1038/s41586-019-1785-z. Epub 2019 Nov 27.
5
Drug-Resistant Bacteremia Transmitted by Fecal Microbiota Transplant.
N Engl J Med. 2019 Nov 21;381(21):2043-2050. doi: 10.1056/NEJMoa1910437. Epub 2019 Oct 30.
6
Epithelial Cells as a Transmitter of Signals From Commensal Bacteria and Host Immune Cells.
Front Immunol. 2019 Aug 28;10:2057. doi: 10.3389/fimmu.2019.02057. eCollection 2019.
7
Sorbitol: Often forgotten cause of osmotic diarrhea.
Can Fam Physician. 2019 Aug;65(8):557-558.
8
Lysine harvesting is an antioxidant strategy and triggers underground polyamine metabolism.
Nature. 2019 Aug;572(7768):249-253. doi: 10.1038/s41586-019-1442-6. Epub 2019 Jul 31.
9
Systematic review with meta-analyses: does the pathogen matter in post-infectious irritable bowel syndrome?
Scand J Gastroenterol. 2019 May;54(5):546-562. doi: 10.1080/00365521.2019.1607897. Epub 2019 May 21.
10
Anti-biofilm and antimicrobial effects of zerumbone against Bacteroides fragilis.
Anaerobe. 2019 Jun;57:99-106. doi: 10.1016/j.anaerobe.2019.04.001. Epub 2019 Apr 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验